SBIR Phase III Commercialization

SBIR Phase III is the commercialization and procurement stage of the SBIR lifecycle, in which technology developed during Phases I and II is acquired by government agencies for operational use or sold to private sector customers, without using SBIR program funds, which are reserved for R&D.

What is SBIR Phase III?

Phase III is not a grant or R&D award, it is a government procurement contract (or non-federal sales) in which the developed technology transitions from the laboratory to operational deployment. Phase III contracts are funded from the procuring agency's regular appropriations, not from the SBIR set-aside, and may be awarded without competition under a statutory authority that permits agencies to award follow-on production contracts to SBIR Phase II awardees.

This non-competitive Phase III award authority, established in the Small Business Act, means that a federal agency that wants to procure technology developed under SBIR does not need to compete the contract if the contractor developed the technology with SBIR funding. This is one of the most significant commercial advantages of winning Phase I and Phase II: the government can place a direct award for operational procurement without a competitive solicitation.

Phase III also encompasses non-federal commercialization. A company may license or sell its SBIR-developed technology to private sector customers, software products, hardware systems, diagnostics, or services, as a parallel or alternative commercialization path to government procurement.

The SBIR program defines Phase III broadly: any work derived from the Phase I or Phase II that is related to the funded research topic, regardless of whether additional SBIR funds are used, is considered Phase III activity. This definition protects the company's ability to access non-competitive Phase III contracts across multiple agencies for the same technology.

Why SBIR Phase III matters for government contractors

Phase III is where SBIR investment pays off most tangibly for both the company and the government. For the company, Phase III can represent multi-million-dollar follow-on contracts without competition. For the government, it represents a streamlined path to acquiring proven innovative technology from the company that developed it with government R&D investment.

Example

A healthcare IT startup completes a Phase II SBIR award with VA for an AI-assisted clinical decision support tool. The tool performs exceptionally well in pilot testing across three VA medical centers. The VA program office issues a non-competitive Phase III contract worth $12 million over five years to deploy the system across the VA's 170 medical centers. The company also licenses the technology to three private health systems, generating additional non-federal Phase III commercialization revenue.

Frequently Asked Questions

Can multiple agencies award Phase III contracts for the same SBIR technology?

Yes. The Phase III non-competitive award authority is available to any federal agency seeking to use technology developed with SBIR funds, not just the funding agency. A DoD SBIR Phase II awardee can receive non-competitive Phase III contracts from DHS, VA, or other agencies that want the same technology.

Is Phase III restricted to the original SBIR awardee?

Generally yes. Phase III contracts are specifically linked to the SBIR awardee that developed the technology. However, if the awardee is acquired or merges with another company, Phase III eligibility may transfer to the successor entity under the right circumstances.

Does Phase III have a dollar limit?

No. Unlike Phase I and Phase II, which have statutory award ceilings, Phase III contracts have no size limit. Phase III contracts can range from small follow-on production orders to multi-hundred-million-dollar acquisition programs.

What happens if a company fails to commercialize after Phase II?

There is no formal penalty for failing to commercialize after SBIR Phase II, but the agency tracks commercialization outcomes and poor commercialization history can affect future award decisions. Agencies increasingly use commercialization history databases when evaluating new SBIR applications from companies with prior Phase II awards.